Paz-Bailey, G; Ramaswamy, M; Hawkes, SJ; Geretti, AM (2007) Herpes simplex virus type 2: epidemiology and management options in developing countries. Sexually transmitted infections, 83 (1). pp. 16-22. ISSN 1368-4973 DOI: https://doi.org/10.1136/sti.2006.020966

Downloaded from: http://researchonline.lshtm.ac.uk/6451/

DOI: 10.1136/sti.2006.020966

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Herpes simplex virus type 2: epidemiology and management options in developing countries

G Paz-Bailey, M Ramaswamy, S J Hawkes, A M Geretti

Genital herpes simplex virus type 2 (HSV2) is highly prevalent worldwide and an increasingly important cause of genital ulcer disease (GUD). Continued HSV2 transmission is facilitated by the large number of undiagnosed cases, the frequency of atypical disease and the occurrence of asymptomatic shedding. The lack of easy, affordable diagnostic methods and specific antiviral treatment in countries with low and middle income is of great concern, given the ability of GUD to enhance HIV transmission and acquisition. With rising HSV2 prevalence contributing to an increase in the proportion of GUD attributed to genital herpes in high-HIV prevalence settings, a safe and effective HSV vaccine is urgently needed. Meanwhile, multifaceted interventions are required to improve recognition of genital herpes, to prevent its spread and also to prevent its potential to promote HIV transmission in developing countries.

Genital herpes infection is the primary cause of genital ulcer disease (GUD) worldwide. It is mainly caused by herpes virus simplex (HSV) type 2 (HSV2) but can also be caused by HSV1. HSV1 has been estimated to cause 30% of cases of primary genital herpes in the US. In developing countries, the proportion of genital herpes caused by HSV1 is unknown, although it is assumed to be low. Recent attention has focused on the role of HSV2 as a cofactor for HIV infection and, hence, HSV2 treatment may have a role as an HIV prevention strategy. The World Health Organization (WHO) has recently issued new guidelines for the syndromic management of genital ulcers, which recommend antiviral treatment for herpes in settings with high HSV2 prevalence. Aciclovir is inexpensive, well tolerated and has an acceptable profile for widespread treatment; however, it is not widely available in countries with low and middle income. While an effective HSV vaccine is available, other treatment and control strategies need to be evaluated and, if effective, implemented.

This paper reviews the epidemiology of HSV2 in developing countries, the importance of HSV2 as a cause of GUD, the available evidence on the interaction between HSV2 and HIV, the diagnostic options in developing countries and the role of antiviral treatment in the management of GUD.

SEARCH METHODS
To identify relevant published literature, we comprehensively searched the Medline database covering studies from 1985 to 2005. The websites of the WHO, US Centers for Disease Control and Prevention, UK Public Health Laboratory Service and UK Medical Society for the Study of Venereal Diseases were also searched for relevant publications and abstracts. Search terms used were “genital herpes”, “STI (sexually transmitted infection)” and “developing countries, genital ulcer, HSV, HSV-2, herpes”. For the review of GUD aetiology in developing countries, we included all papers that reported laboratory methods used, and we excluded those that provided only clinical diagnosis.

HSV2 EPIDEMIOLOGY
Few countries have population-based national estimates of HSV2 that allow the estimation of seroprevalence trends. In the US, a representative national sample of the population aged >12 years indicated that age-adjusted HSV2 prevalence has increased from 16.4% to 21.7% of adults from 1976 to 1994. European cross-sectional surveys conducted between 1989 and 2000 found that age-standardised HSV2 seroprevalence ranged from 4% in England and Wales to 24% in Bulgaria.

Compared with developing countries, substantially higher rates of HSV2 have been observed in sub-Saharan Africa, with age-adjusted prevalences in adults ranging from 30% to 80% in women and 10% to 50% in men (fig 1). In South America, available data are mainly for women, in whom HSV2 prevalence ranges from 20% to 40%. Prevalence in the general population in Asian countries shows lower values, from 10% to 30%.

The changing epidemiology of GUD
The prevalence and aetiology of GUD in different geographical regions and populations in Africa seem to vary widely, and are also changing over time. Studies on GUD in developing countries published before 1995 identified syphilis and chancroid as the main causes of GUD (table 1). In resource-poor nations, the spread of HIV and factors such as enhanced case identification and treatment for bacterial GUD since 1990 seem to have resulted in altered epidemic patterns of sexually transmitted infections (STIs). Among studies conducted during the past 10 years, HSV2 has been reported as an important cause of GUD in Africa, South East Asia and Latin America. In at least seven locations in Africa where longitudinal data are available, there is evidence of a shift in the aetiology of GUD towards HSV2 (table 1). For example, cross-sectional studies among miners in South Africa reported that the

Abbreviations: GUD, genital ulcer disease; HSV, herpes simplex virus; PCR, polymerase chain reaction; STI, sexually transmitted infection; WHO, World Health Organization
proportion of ulcers due to herpes increased from 3% in 1986 to 17% in 1994 and to 36% in 1998. Paz-Bailey et al. reported similar findings from Botswana, where 24% of GUD among patients with STIs was due to HSV2 in 1993, increasing to 60% in 2002. In Botswana, the increases in HSV2 were still marked after adjusting the prevalence for the differences in sensitivity and specificity of diagnostic tests used in 1993 and 2002.

Possible explanations for the changes in GUD aetiology include changes in laboratory techniques, HIV-attributable mortality among high-risk groups, behavioural change, improved syndromic management and increase in antibiotic use. Changes in laboratory techniques, including availability of more sensitive tests such as polymerase chain reaction (PCR), may explain some of the differences but cannot account for all the observed changes in prevalence. Similarly, HIV-attributable mortality might disproportionately affect the prevalence of chancroid, which heavily relies on core groups to persist. In contrast, owing to its longer duration of infection, HSV2 does not rely on people at high risk to spread and is less influenced by the differential mortality associated with AIDS. Syndrome management was implemented in several countries in Africa in the early 1990s, and widespread use of antibiotics, together with mandatory serological testing for syphilis, may have contributed to a decrease in the prevalence of syphilis and other STIs.

**HSV2 AND HIV**

An increasing body of literature suggests that HIV and HSV2 manifest bidirectional interactions. Clinical, biological and epidemiological studies support the hypothesis that HSV2 increases the efficiency of HIV acquisition and transmission. Similarly, HIV may increase susceptibility to HSV2. HSV2 shedding and, at low CD4 counts, severity of clinical manifestations. In terms of HIV acquisition, HSV2 can cause ulcers and microulcerations, and GUD has been associated with a 7–11-fold risk of HIV acquisition in cohort studies. In a meta-analysis of the epidemiological literature of HSV2 and the risk of HIV infection, cohort and nested case-control studies showed an increased risk of acquiring HIV in HSV2-seropositive heterosexual men (risk ratio (RR) 2.7, 95% confidence interval (CI) 1.9 to 3.9), men who have sex with men (RR 1.7, 95% CI 1.2 to 2.4), and women from the general population (RR 3.1, 95% CI 1.7 to 5.6). Among high-risk women, RR values ranged widely, and the summary estimate did not show a significant association (RR 1.0, 95% CI 0.5 to 2.0). HIV acquisition risk is highest among those with recent HSV2 infection, which may reflect the higher frequency and severity of herpetic ulcers during the early stages of HSV2.

HSV2 infection may enhance HIV and HSV2 transmission among people with coinfection. HIV RNA has been isolated from herpetic lesions, and clinically recurrent herpes and asymptomatic shedding is associated with transient increases in HIV load in plasma and genital secretions. These findings suggest that HSV2 reactivation may increase HIV infectiousness. Gray et al. studied HIV transmission rates per sex act among HIV-discordant monogamous couples in Rakai, Uganda. The two most important risk factors for HIV transmission were the presence of genital ulcers and higher HIV plasma load. Most GUDs in Rakai (87% of all ulcers with known aetiology) were due to HSV2.

**Genital herpes in people with HIV infection**

Although clinical observations suggest that patients with HIV have more frequent and prolonged episodes, few studies have examined the effect of HIV on the natural history of HSV2 infection. The influence of immunodeficiency on the clinical manifestations of HSV2 infection is complex, and although impaired T cell function is expected to increase HSV2 re-activation rates and shedding, it may also reduce the host inflammatory response, and therefore the clinical expression of HSV2 infection. Consistent with this hypothesis, HSV2 infection has been included as a possible manifestation of the immunoreconstitution syndrome induced by highly active antiretroviral therapy. Available data from cohort studies among people with dual infections do not show more symptomatic herpes manifestations among HIV-positive people but do show increased HSV2 shedding. Schacker et al. showed that HSV status had only a modest effect on the rate and duration of clinical recurrences (0.34 < 0.23 recurrences per month among HIV-negative people); however, the rate of subclinical shedding was markedly higher among HIV-positive people.

Ramaswamy et al. followed up 549 HIV/HSV2-infected people and reported that only 21% had a clinical diagnosis of genital herpes over a median 5 years of follow-up.

**LABORATORY DIAGNOSIS OF GENITAL HERPES: OPTIONS FOR RESOURCE-LIMITED SETTINGS**

**Virus detection in genital swabs**

Virus isolation in cell culture has long been considered the diagnostic gold standard for HSV. Specificity is virtually 100%, but levels of virus shedding, specimen quality and transport conditions influence sensitivity. Test performance declines with time since the onset of lesions and is on average 52–93% for vesicles, 41–72% for ulcers and 19–27% for crusted lesions. PCR increases the sensitivity of culture by 11–75%, and it has recently been recommended as the new diagnostic gold standard for genital herpes. Additional methods include detection of viral antigen by direct immunofluorescence assay using fluorescein-labelled monoclonal antibodies on smears, or by enzyme immunoassay on swabs. Immunofluorescence is expensive and shows lower sensitivity (74%) and specificity (83%) than virus culture. Antigen enzyme immunoassay shows >95% specificity and 62–100% sensitivity relative to virus culture.

**HSV2-specific serology**

Commercially available assays to detect antibodies to HSV2-specific glycoprotein gG-2 have markedly improved serological diagnosis of HSV2 infection over the past 10 years. These tests have been evaluated in industrialised countries, and their sensitivity against western blot ranged from 93% to 100%, and the specificity ranged from 95% to 100%. Recent evaluations of
<table>
<thead>
<tr>
<th>City, country, reference</th>
<th>Aetiology of genital ulcer disease, n (%)</th>
<th>Serology, n (%)</th>
<th>Laboratory techniques</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aetiology</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TP, HD, HSV, LGV</td>
<td>Mixed aetiology</td>
<td>No detection</td>
</tr>
<tr>
<td><strong>Africa</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gaborone, Botswana</td>
<td>1993</td>
<td>108 M, F</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Gaborone, Francistown and Seleka, Phikwe, Botswana</td>
<td>2002</td>
<td>137 M, F</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Nairobi, Kenya</td>
<td>1985</td>
<td>89 F</td>
<td>11 (12)</td>
</tr>
<tr>
<td>Nairobi, Kenya</td>
<td>1985</td>
<td>115 M</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Nairobi, Kenya</td>
<td>1990–1</td>
<td>168 M, F</td>
<td>NR</td>
</tr>
<tr>
<td>Nairobi, Kenya</td>
<td>1995–7</td>
<td>245 M, F</td>
<td>86 (36)</td>
</tr>
<tr>
<td>Masera, Lesotho</td>
<td>1993–4</td>
<td>105 M, F</td>
<td>23 (23)</td>
</tr>
<tr>
<td>Blantyre, Malawi</td>
<td>1993</td>
<td>778 M</td>
<td>136 (20)</td>
</tr>
<tr>
<td>Lilongwe, Malawi</td>
<td>1998–9</td>
<td>137 M, F</td>
<td>5 (4)</td>
</tr>
<tr>
<td>Antananarivo, Madagascar</td>
<td>1997</td>
<td>196 M, F</td>
<td>56 (29)</td>
</tr>
<tr>
<td>Kigali, Rwanda</td>
<td>1986</td>
<td>210 M, F</td>
<td>63 (30)</td>
</tr>
<tr>
<td>Kigali, Rwanda</td>
<td>1990–2</td>
<td>395 M, F</td>
<td>110 (28)</td>
</tr>
<tr>
<td>Dakar, Senegal</td>
<td>1992</td>
<td>39 M, F</td>
<td>25 (10)</td>
</tr>
<tr>
<td>Carletonville, South Africa</td>
<td>1999</td>
<td>240 M</td>
<td>6 (15)</td>
</tr>
<tr>
<td>Carletonville, South Africa</td>
<td>1993–4</td>
<td>232 M</td>
<td>24 (10)</td>
</tr>
<tr>
<td>Carletonville, South Africa</td>
<td>1998</td>
<td>186 M</td>
<td>23 (12)</td>
</tr>
<tr>
<td>Cape Town, South Africa</td>
<td>1993–4</td>
<td>180 M</td>
<td>59 (33)</td>
</tr>
<tr>
<td>Johannesburg, South Africa</td>
<td>1993–4</td>
<td>159 M</td>
<td>19 (10)</td>
</tr>
<tr>
<td>Durban, South Africa</td>
<td>1984</td>
<td>100 M</td>
<td>23 (23)</td>
</tr>
<tr>
<td>Durban, South Africa</td>
<td>1988–9</td>
<td>100 M</td>
<td>42 (42)</td>
</tr>
<tr>
<td>Durban, South Africa</td>
<td>1988–9</td>
<td>100 F</td>
<td>40 (40)</td>
</tr>
<tr>
<td>Durban, South Africa</td>
<td>1993–4</td>
<td>199 M</td>
<td>29 (15)</td>
</tr>
<tr>
<td>Dar es Salaam and Mbeya, Tanzania</td>
<td>2000–1</td>
<td>587 M, F</td>
<td>85 (14)</td>
</tr>
<tr>
<td>Dar es Salaam and Mbeya, Tanzania</td>
<td>1999</td>
<td>102 M, F</td>
<td>1 (1)</td>
</tr>
</tbody>
</table>

Table 1: Review of aetiology of genital ulcer disease in Africa, Asia and Latin America
These findings could be due to problems of cross-reactivity, the fact that some tests detect HSV2 seroconversion earlier than others, including western blot. It has been recommended that the threshold for calculating positive results should be increased as a way of improving specificity, although this may also reduce sensitivity in early infection.

The role of routine laboratory investigations

The cost-benefit ratio of adopting virus detection and HSV2-specific serology for routine management of patients attending STI clinics in developing countries remains currently uncertain. Given that the clinical diagnosis of genital herpes is typically unreliable, a laboratory confirmation is desirable. Antigen enzyme immunoassay may be an option for resource-limited settings, as assays are commercially available and easy to perform, but the test is expensive and its sensitivity is suboptimal. Although PCR allows less stringent conditions for sample storage and transport than virus culture and can be highly automated, it requires sophisticated laboratory equipment, high-level technical expertise and strict quality control. These conditions combined make PCR a difficult diagnostic option in most resource-limited settings. Centralised laboratory facilities may be one method of providing testing. Although results may not be available for immediate patient management, important information is gained on local epidemiology of GUD and the validity of syndromic approaches to GUD management, thus assisting programme managers in evidence-based decision making.

Similar considerations apply to the use of HSV-specific serology for screening purposes, given that the tests are expensive and in many settings infection with HSV2 is nearly universal among patients with GUD. The strongest argument in favour of screening is that HSV2-seropositive people can be counselled about the increased risk of HIV acquisition. Thus, the scope for using HSV2 serology to detect infected people may grow in developing countries should evidence from ongoing studies support the use of antiviral treatment against HSV2 as a strategy for HIV prevention. In this case, serological screening could be considered to identify people coinfected with both viruses who could benefit from suppressive anti-HSV2 treatment. This might be especially important for couples with discordant HSV2/HIV serostatus.

CURRENT TREATMENT STRATEGIES

Antiviral treatment

For bacterial STI, treatment is usually short and aimed at both reducing the duration and severity of symptoms and eliminating the aetiological agent. For viral STI such as herpes, treatment can be either short and episodic, which will reduce the severity and duration of symptomatic recurrences, or longer-term suppressive treatment, which will reduce both the number and severity of symptomatic episodes and asymptomatic shedding. Episodic treatment in recurrent episodes reduces pain, decreases time to ulcer healing by 1–2 days and reduces HSV2 shedding by 1–2 days, although it has no effect on recurrence rates. Suppressive treatment with aciclovir can prevent or delay 80% of recurrences, and reduce clinical and subclinical shedding by >90%. Aciclovir’s pharmaceutical patent has recently expired and the drug is now available in generic form from nine manufacturers in seven countries worldwide for <$US$0.20 per tablet.

<table>
<thead>
<tr>
<th>City, country, reference</th>
<th>Year</th>
<th>Population</th>
<th>TP</th>
<th>HD</th>
<th>HSV</th>
<th>LGV</th>
<th>Mixed aetiology</th>
<th>No detection</th>
<th>HSV2</th>
<th>Syphilis</th>
<th>HIV</th>
<th>Laboratory techniques</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dar es Salaam, Tanzania</td>
<td>1980</td>
<td>104 M, F</td>
<td>5 (5)</td>
<td>54 (52)</td>
<td>4 (4)</td>
<td>7 (7)</td>
<td>28 (27)</td>
<td>22 (21)</td>
<td>55 (80)</td>
<td>29 (42)</td>
<td></td>
<td>TP, HD and HSV MPCR; HSV2 serology ELISA; HIV ELISA</td>
</tr>
<tr>
<td>Fajara, The Gambia</td>
<td>1990–1</td>
<td>98 M, F</td>
<td>2 (2)</td>
<td>0 (0)</td>
<td>35 (36)</td>
<td>0 (0)</td>
<td>2 (2)</td>
<td>61 (61)</td>
<td>11 (12)</td>
<td>58 (65)</td>
<td></td>
<td>TP dark field TP; HD, CT and HSV culture; syphilis VDRL-TPHA; CT serology MIF</td>
</tr>
<tr>
<td>Kampala, Uganda</td>
<td>1994–8</td>
<td>207 M, F</td>
<td>8 (4)</td>
<td>6 (3)</td>
<td>89 (43)</td>
<td>NR</td>
<td>NR</td>
<td>103 (51)</td>
<td>NR</td>
<td>0</td>
<td></td>
<td>TP, HD, HSV MPCR; syphilis serology TRUST-TPHA; HIV ELISA-western blot</td>
</tr>
<tr>
<td>Rakai, Uganda</td>
<td>1994–90</td>
<td>249 M, F</td>
<td>18 (7)</td>
<td>22 (9)</td>
<td>48 (19)</td>
<td>4 (2)</td>
<td>3 (1)</td>
<td>153 (62)</td>
<td>41 (17)</td>
<td>NR</td>
<td></td>
<td>TP dark field TP; HD, CT and HSV culture; syphilis serology VDRL-FTA-abs; HIV ELISA-western blot</td>
</tr>
<tr>
<td>Asia</td>
<td>1995–6</td>
<td>38 M, F</td>
<td>1 (3)</td>
<td>0 (0)</td>
<td>32 (84)</td>
<td>NR</td>
<td>1</td>
<td>6 (16)</td>
<td>NR</td>
<td>11 (46)</td>
<td></td>
<td>TP, HD, HSV MPCR; HIV test NR</td>
</tr>
<tr>
<td>Asia</td>
<td>1995–6</td>
<td>81 M</td>
<td>4 (5)</td>
<td>21 (26)</td>
<td>35 (43)</td>
<td>NR</td>
<td>0</td>
<td>21 (26)</td>
<td>NR</td>
<td>6 (7)</td>
<td>11 (14)</td>
<td>TP, HD, HSV MPCR; syphilis serology VDRL-FTA-abs; HIV ELISA-western blot</td>
</tr>
<tr>
<td>Asia</td>
<td>1996</td>
<td>304 M, F</td>
<td>31 (10)</td>
<td>72 (24)</td>
<td>158 (52)</td>
<td>NR</td>
<td>22 (7)</td>
<td>67 (22)</td>
<td>NR</td>
<td>64 (21)</td>
<td>67 (22)</td>
<td>TP, HD, HSV MPCR; syphilis serology TRUST-THA-TP; HIV ELISA-western blot</td>
</tr>
<tr>
<td>Asia</td>
<td>1996</td>
<td>63 M</td>
<td>6 (10)</td>
<td>3 (5)</td>
<td>27 (43)</td>
<td>NR</td>
<td>3 (5)</td>
<td>30 (48)</td>
<td>NR</td>
<td>5 (8)</td>
<td>2 (3)</td>
<td>TP, HD, HSV MPCR; syphilis serology RPR-TPHA; HIV ELISA-western blot</td>
</tr>
</tbody>
</table>
Addition of aciclovir to the syndromic management of GUD

Previous WHO guidelines for the treatment of GUD were concerned with bacterial aetiologies and provided no suggestions for effective treatment for genital herpes. Owing to the observed increases in the worldwide prevalence of HSV2 infection, the WHO now recommends giving ant herpes treatment in places where the relative prevalence of HSV2 infection is >30%. Botswana is the first country in Africa to incorporate aciclovir treatment for GUD management, and the government is closely monitoring its implementation. However, some questions about the incorporation of antitherpes treatment into syndromic management still remain. Firstly, evidence on the effect of episodic aciclovir treatment on ulcer duration suggests that it is primarily effective when given early, ideally at ulcer onset. Under field conditions, patients attending primary healthcare facilities are likely to have a delay in symptom recognition, and thus there is a delay in initiating treatment. Treatment strategies will have to be accompanied by successful campaigns targeting early symptom recognition and prompt treatment. Secondly, unnecessary overtreatment might become more common, as syphilis and chancroid are becoming rare, and herpes is responsible for most cases of GUD. Treatment for these bacterial infections will probably have to continue for several years until syphilis and chancroid are eliminated. The WHO is currently assembling a 5-year control initiative for genital ulcers, with the goal of eliminating chancroid and reducing the prevalence of syphilis. Thirdly, it is still unclear how partner notification for herpes contacts will be implemented. Although many patients are infected by asymptomatic partners, some may be taught to recognise signs and symptoms of genital herpes that were previously unrecognised. Counselling would provide an opportunity for health education, condom promotion, HIV testing and reinforcing abstention from sexual intercourse while lesions are present. Finally, further adjustment to algorithms for GUD management will be needed in areas with a high prevalence of HIV where delayed healing of ulcers and multiple recurrences are already an increasing problem. These patients would greatly benefit from suppressive treatment.

Trials are currently under way in South Africa, Ghana and Malawi to evaluate the incorporation of aciclovir into the syndromic management of GUD and its effect on reduction of pain, ulcer healing and HIV shedding from ulcers (table 2). The cost effectiveness of this strategy needs to be determined.

Treatment of genital herpes for the prevention of acquisition and transmission of HIV

As antiviral treatment can reduce virus shedding and viral loads, it has been hypothesised that they also reduce transmis- sion of HSV2 and HIV infections. The first trial to assess the effect of antiviral treatment on the heterosexual transmission of a viral infection has been completed recently. Provision of suppressive treatment was shown to reduce HSV2 transmission. A multicentre study among monogamous, heterosexual, HSV2-discordant couples found that a once-daily suppressive dose of valaciclovir reduced the incidence of symptomatic genital herpes among the uninfected by 77% and the overall risk of transmission by 50%. Several trials are under way to evaluate the effect of antitherpes treatment in reducing HIV transmission and acquisition. These trials are considering the following public health issues:

1. Reducing the enhancing effect of HSV2 on HIV, by episodic treatment of genital herpes in populations with high risk of transmission or acquisition of HIV (ie patients with STI)
2. Suppression of HSV2, to reduce susceptibility to HIV among HSV-negative, HSV2-seropositive people

Encouraging data were recently presented by Nagot et el showing that suppressive treatment with valaciclovir reduced
HIV vaginal shedding and HIV plasma load among women with dual infections.

OTHER HERPES INTERVENTIONS

Condom use
Few studies have evaluated the protection provided by condoms against genital herpes. Most cross-sectional studies have failed to show an association and even suggest increased risk among men using condoms, probably because condom use is a marker of high-risk relationships. One prospective study reported protection from condom use only among women. A more recent study showed that participants reporting more frequent condom use (condom use for >75% of sexual acts) were at a lower risk of acquiring HSV2 (hazard ratio 0.7, 95% CI 0.6 to 0.9).23

HSV2 vaccines
Although animal studies on vaccination strategies to prevent genital and neonatal herpes may be promising, clinical trials of HSV2 vaccines in humans have failed to prove efficacy.1 In a recent study, an HSV2 glycoprotein D vaccine using alum as adjuvant induced protection from clinical disease (73%) and overall HSV2 transmission (about 40%).24 By contrast, no protective efficacy was observed with a similar vaccine based on the viral glycoproteins B and D and using MF59 as adjuvant.25 The protective effect of the MPL vaccine was seen only in women who were HSV1 and HSV2 seronegative, and there was no protection among men or among HSV1-seropositive women.26 The partial efficacy was shown to be related to the induction of T cell immunity with a T helper 1 profile. The vaccine is currently being evaluated in a large multicentre trial targeting pre-pubertal girls.

DISCUSSION

HSV2 is highly prevalent in most regions, especially those experiencing HIV epidemics, and it has become the most important cause of GUD worldwide. In addition to the suffering and expense incurred by people with HSV2 infections, substantial data support an important role of HSV2 in facilitating HIV transmission and acquisition.

As with all STIs, the most cost-effective intervention is primary prevention. However, STI control has been successful only in a limited number of settings, and primary prevention programmes have obstacles of acceptance and effectiveness among populations who are both vulnerable and at risk. Given the epidemiology of HSV2 acquisition as primarily an incident infection among young people, we should undoubtedly be focusing primary prevention efforts on this age group, especially in resource-poor settings where incidence and prevalence remain highest. Primary prevention should include delaying sexual debut among adolescents and reducing the number of sexual partners. Male condoms protect against HSV2 less effectively than against HIV, but still have some efficacy.27 Given the strong efficacy of condoms in protecting against HIV and other STIs, promotion of condom use should always be included in any STI prevention effort.

Once infected with HSV2, a lifelong viral infection requires different management strategies compared with managing “one-off” bacterial infections. Although conventional wisdom may have mitigated against the cost effectiveness of trying to control a recurrent infection in resource-poor settings, increasing evidence of the interaction between HSV2 infection and the risk of HIV transmission, and the increasing contribution of HSV2 to the burden of GUD, has raised the salience of HSV2. Whether providing suppressive or episodic antiviral treatment, more attention should be focused on ensuring that people infected with HSV2 have access to appropriate and effective care. Services should be part of a prevention package including HIV testing and counselling to all patients with STI, counselling to improve recognition of herpes symptoms, early initiation of episodic aciclovir treatment and counselling on condom use, and abstaining from sexual intercourse during herpes outbreaks.

Prevention and treatment strategies should be first targeted at people with genital herpes lesions. Although these may be a small proportion of those who are HSV2 seropositive, people with lesions are at highest risk of transmitting the virus. Questions on the effect of antiretroviral treatment in preventing HIV transmission and acquisition remain unanswered. Ongoing trials will assist in filling these knowledge gaps and will provide the evidence required to design new interventions for herpes. In countries in sub-Saharan Africa, where the prevalence of HSV2 is extremely high, the provision of aciclovir for people with genital ulcers who are being treated syndromically might represent the most cost-effective and easiest means to implement a strategy for HIV prevention.

While the inclusion of herpes treatment in syndromic management is further evaluated on the basis of current WHO and US STI management recommendations,27 aciclovir should be made available for patients with primary herpes (although hard to identify in developing countries), those with severe episodes, immunosuppressed patients and patients with frequent recurrences. Developing countries should also consider adding aciclovir to the essential drug list. Further, with the help of WHO, aciclovir should be made available and affordable in developing countries.

REFERENCES


Authors’ affiliations
G Paz Bailley, Global AIDS Program for Central America National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
S J Hawkes, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
M Ramaswamy, A M Geretti, Department of Virology, Royal Free Hospital and Royal Free and University College Medical School, London, UK

Competing interests: None declared.
The etiology and management of genital ulcer disease in men in Africa: opportunity for intervention.


